What is PreciPoint?
PreciPoint specializes in advanced digital live microscopy technology, engineered for immediate on-site evaluation within pathology workflows. The company's flagship offering, the iO:M8, provides sophisticated imaging capabilities tailored for medical professionals. PreciPoint's mission is to equip healthcare providers and pathologists with efficient diagnostic tools, thereby enhancing the speed and precision of pathological assessments through continuous innovation.
How much funding has PreciPoint raised?
PreciPoint has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2022): $10M with participation from bm-t beteiligungsmanagement thüringen
Key Investors in PreciPoint
bm-t beteiligungsmanagement thüringen
bm|t is a venture capital and private equity firm that supports innovative and growth-oriented companies in Thuringia with capital investments and risk capital. As a participation company of the Free State of Thuringia, it invests in businesses with significant future potential across various investment stages.
What's next for PreciPoint?
The substantial enterprise-level funding PreciPoint has garnered, particularly the recent strategic investment, signals a pivotal growth phase. This capital infusion is expected to accelerate product development, expand market reach, and further solidify its position in the competitive digital pathology landscape. The company is poised to leverage this financial momentum to drive innovation and scale its operations, aiming to become a leader in on-site diagnostic imaging solutions.
See full PreciPoint company page
